CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria Richon, Ph.D., President and CEO, will provide a corporate overview and an update on the company’s lead clinical program, PARP7 inhibitor RBN-2397, at the Jefferies 2020 Virtual Healthcare Conference.
Jefferies Virtual Healthcare Conference – June 2-4, 2020
Presenter: Victoria Richon, Ph.D. – President and CEO
Date: June 2, 2020
Time: 3:00 p.m. EDT
About Ribon Therapeutics
Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information visit www.RibonTx.com